{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cetuximab&page=15", "query": { "intervention": "cetuximab", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 559, "total_pages": 56, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cetuximab&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=cetuximab&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T21:38:06.402Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00112346", "title": "Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Carcinoma" ], "interventions": [ { "name": "Cetuximab + platinum + gemcitabine", "type": "DRUG" }, { "name": "Platinum + Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2005-01", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-10-26T21:38:06.402Z", "location_count": 31, "location_summary": "Mobile, Alabama • Anchorage, Alaska • Bakersfield, California + 28 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Bakersfield", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Oxnard", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00112346" }, { "nct_id": "NCT01416688", "title": "S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Colorectal Cancer", "Dermatologic Complications", "Lung Cancer", "Therapy-related Toxicity" ], "interventions": [ { "name": "assessment of therapy complications", "type": "PROCEDURE" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 146, "start_date": "2011-11-15", "completion_date": "2019-04-08", "has_results": false, "last_update_posted_date": "2022-12-15", "last_synced_at": "2026-10-26T21:38:06.402Z", "location_count": 113, "location_summary": "Tucson, Arizona • Castro Valley, California • Duarte, California + 78 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Castro Valley", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Dublin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01416688" }, { "nct_id": "NCT05067283", "title": "A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Calderasib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 830, "start_date": "2021-12-17", "completion_date": "2030-02-25", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-26T21:38:06.402Z", "location_count": 6, "location_summary": "Tampa, Florida • Grand Rapids, Michigan • Hackensack, New Jersey + 3 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05067283" }, { "nct_id": "NCT06704724", "title": "A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Pancreatic Ductal", "Colorectal Neoplasms", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "PF-07985045", "type": "DRUG" }, { "name": "Gemcitabine", "type": "COMBINATION_PRODUCT" }, { "name": "Nab-paclitaxel", "type": "COMBINATION_PRODUCT" }, { "name": "Cetuximab", "type": "COMBINATION_PRODUCT" }, { "name": "Fluorouracil", "type": "COMBINATION_PRODUCT" }, { "name": "Oxaliplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Leucovorin", "type": "COMBINATION_PRODUCT" }, { "name": "Bevacizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Pembrolizumab", "type": "COMBINATION_PRODUCT" }, { "name": "Sasanlimab", "type": "COMBINATION_PRODUCT" }, { "name": "pemetrexed", "type": "COMBINATION_PRODUCT" }, { "name": "Cisplatin", "type": "COMBINATION_PRODUCT" }, { "name": "Paclitaxel", "type": "COMBINATION_PRODUCT" }, { "name": "Carboplatin", "type": "COMBINATION_PRODUCT" }, { "name": "PF-07284892", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-12-10", "completion_date": "2026-05-12", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-10-26T21:38:06.402Z", "location_count": 12, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06704724" }, { "nct_id": "NCT00321100", "title": "Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "bevacizumab", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2006-04-12", "completion_date": "2013-12-18", "has_results": true, "last_update_posted_date": "2022-01-12", "last_synced_at": "2026-10-26T21:38:06.402Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00321100" }, { "nct_id": "NCT02057107", "title": "SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Previously-Irradiated", "Squamous Cell Carcinoma of the Head and Neck Cancer" ], "interventions": [ { "name": "SBRT", "type": "RADIATION" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Heath Skinner", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2013-07-03", "completion_date": "2019-12-31", "has_results": false, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-10-26T21:38:06.402Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02057107" }, { "nct_id": "NCT02014909", "title": "A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer" ], "interventions": [ { "name": "KTN3379", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2014-01", "completion_date": "2017-06-05", "has_results": false, "last_update_posted_date": "2017-07-24", "last_synced_at": "2026-10-26T21:38:06.402Z", "location_count": 5, "location_summary": "Denver, Colorado • New Haven, Connecticut • Detroit, Michigan + 2 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02014909" }, { "nct_id": "NCT01015664", "title": "Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "temsirolimus", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Tennessee Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2010-02", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2012-12-17", "last_synced_at": "2026-10-26T21:38:06.402Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01015664" }, { "nct_id": "NCT00101348", "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Colon Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Pancreatic Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage III Adenoid Cystic Carcinoma of the Oral Cavity", "Stage III Basal Cell Carcinoma of the Lip", "Stage III Colon Cancer", "Stage III Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage III Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage III Lymphoepithelioma of the Nasopharynx", "Stage III Lymphoepithelioma of the Oropharynx", "Stage III Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage III Mucoepidermoid Carcinoma of the Oral Cavity", "Stage III Pancreatic Cancer", "Stage III Rectal Cancer", "Stage III Salivary Gland Cancer", "Stage III Squamous Cell Carcinoma of the Hypopharynx", "Stage III Squamous Cell Carcinoma of the Larynx", "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage III Squamous Cell Carcinoma of the Nasopharynx", "Stage III Squamous Cell Carcinoma of the Oropharynx", "Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage III Verrucous Carcinoma of the Larynx", "Stage III Verrucous Carcinoma of the Oral Cavity", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Colon Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Pancreatic Cancer", "Stage IV Rectal Cancer", "Stage IV Renal Cell Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2005-01", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2014-06-11", "last_synced_at": "2026-10-26T21:38:06.402Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101348" }, { "nct_id": "NCT03428958", "title": "A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer", "Colorectal Neoplasms", "Colorectal Carcinoma", "Colorectal Tumors", "Neoplasms, Colorectal" ], "interventions": [ { "name": "NUC-3373 + leucovorin", "type": "DRUG" }, { "name": "NUC-3373", "type": "DRUG" }, { "name": "NUFOX", "type": "DRUG" }, { "name": "NUFOX + VEGF pathway inhibitor", "type": "DRUG" }, { "name": "NUFOX + EGFR inhibitor", "type": "DRUG" }, { "name": "NUFIRI", "type": "DRUG" }, { "name": "NUFIRI + VEGF pathway inhibitor", "type": "DRUG" }, { "name": "NUFIRI + EGFR inhibitor", "type": "DRUG" }, { "name": "NUC-3373 + bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NuCana plc", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2018-10-05", "completion_date": "2024-03-21", "has_results": true, "last_update_posted_date": "2025-04-23", "last_synced_at": "2026-10-26T21:38:06.402Z", "location_count": 6, "location_summary": "Boston, Massachusetts • Durham, North Carolina • Nashville, Tennessee + 2 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03428958" } ] }